For biotech, they tend to go to public markets pretty early, while the drug is still in development/approval pipeline due to the high upfront investments, much

For biotech, they tend to go to public markets pretty early, while the drug is still in development/approval pipeline due to the high upfront investments, much like EV firms who have high capital costs. Prior to that I'd assume private investors/VC, but that's a guess.